At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Jun 12, 2026 at 07:00 ET
BioCryst presented updated clinical data at EAACI 2026, including 48-week ORLADEYO pediatric results showing sustained HAE attack reductions and a post hoc analysis of Phase 1b/2 navenibart data supporting ongoing Phase 3 evaluation. The press release contains no new revenue, earnings, or financial guidance, it is a clinical data update with routine positive framing.
- ORLADEYO 48-week data in pediatric HAE (APeX-P; n=29) showed median adjusted attack rate fell from 0.691/month (SOC) to 0.169/month on treatment.
- Attacks requiring professional care dropped from 22 (SOC 12wk) to 3 (first 12wk on ORLADEYO), reaching 0 in weeks 37-48.
- Phase 1b/2 ALPHA-STAR post hoc analysis (navenibart, n=29) showed consistent HAE attack reductions across baseline attack rate, BMI, and age subgroups.
- No severe or serious treatment-emergent adverse events reported for navenibart; most common TEAEs were headache, nasopharyngitis, and UTI.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access